<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110794</url>
  </required_header>
  <id_info>
    <org_study_id>18277</org_study_id>
    <secondary_id>J2A-MC-GZGJ</secondary_id>
    <nct_id>NCT05110794</nct_id>
  </id_info>
  <brief_title>A Multiple-Dose Study of LY3502970 in Healthy Participants</brief_title>
  <official_title>A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in&#xD;
      the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in&#xD;
      fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970&#xD;
      in these participants. The study will last up to 49 days excluding the screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2021</start_date>
  <completion_date type="Anticipated">February 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970</measure>
    <time_frame>Predose up to 41 days postdose</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of LY3502970</measure>
    <time_frame>Predose up to 41 days postdose</time_frame>
    <description>PK: AUC0-24 of LY3502970</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time to Maximum Observed Concentration (Tmax) of LY3502970</measure>
    <time_frame>Predose up to 41 days postdose</time_frame>
    <description>PK: Tmax of LY3502970</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3502970 (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3502970 administered orally to participants who are in a fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 (Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3502970 administered orally to participants who are in a fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered Orally.</description>
    <arm_group_label>LY3502970 (Fasted)</arm_group_label>
    <arm_group_label>LY3502970 (Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation.&#xD;
&#xD;
          -  Participants with body weight of 45 kilograms (kg) or more and body mass index (BMI)&#xD;
             of 18.5 to 35.0 kilograms per meter squared (kg/mÂ²).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have an abnormal blood pressure and/or pulse rate, deemed to be&#xD;
             clinically significant by the investigator at screening.&#xD;
&#xD;
          -  Participants who used or intend to use over-the-counter (OTC) or prescription&#xD;
             medication and/or herbal/vitamin/traditional medicines or mineral supplements that may&#xD;
             affect the safety or objectives of the study, within 14 days prior to dosing and for&#xD;
             the duration of the study. Paracetamol and Covid-19 vaccinations are permitted.&#xD;
&#xD;
          -  Participants who are currently enrolled in a clinical study involving an&#xD;
             investigational product (IP) or any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Participants who show evidence of human immunodeficiency virus (HIV) infection and/or&#xD;
             positive HIV antibodies. A negative test within 6 months of screening would not need&#xD;
             to be repeated.&#xD;
&#xD;
          -  Participants who show evidence of hepatitis C and/or positive hepatitis C antibody. A&#xD;
             negative test within 6 months of screening would not need to be repeated.&#xD;
&#xD;
          -  Participants who show evidence of hepatitis B, positive hepatitis B surface antigen,&#xD;
             and/or positive hepatitis B core antibody. A negative test within 6 months of&#xD;
             screening would not need to be repeated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>64139930</phone>
    </contact>
    <investigator>
      <last_name>Greg Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food</keyword>
  <keyword>Food Effect</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

